Company Encyclopedia
View More
name
HAIXI PHARMA
02637.HK
Fujian Haixi Pharmaceuticals Co., Ltd. manufactures and sells pharmaceutical drugs in China. The company offers drugs for oncology, ophthalmology, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It sells its products through retail pharmacies, online pharmacies, and internet medical platforms.
1.409 T
02637.HKMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Top 10 HK Stock Gainers (12.16)

    ZHEJIANG SHIBAO(01057) rose 12.9%, with a trading turnover 326.5 Million HKD, and a year-to-date rose 58.8%. EASY SMART GP(02442) rose 12.39%, with a trading turnover 16.8 Million HKD, and a year-to-date rose 900%. MINIEYE(02431) rose 8.98%, with a trading turnover 182.9 Million HKD, and a year-to-date fell 44.5%.

    Top Gainers & Losers·
    HK
    01057
    +0.44%
    HK
    02442
    +0.81%
    HK
    02431
    +2.19%
    Top Gainers & Losers·
    HK
    01057
    +0.44%
    HK
    02442
    +0.81%
    HK
    02431
    +2.19%

    Understanding the Market | HAIXI PHARMA once rose over 12%, more than 30% higher than the offering price, with a dual-line layout of generic drugs and innovative drugs

    HAIXI PHARMA once rose over 12%, reaching HKD 114.9, an increase of over 30% compared to the offering price of HKD 86.4. As of the time of writing, it has risen 9.2%, trading at HKD 111.6, with a transaction volume of HKD 20.9312 million. It is reported that HAIXI PHARMA is a pharmaceutical company in the commercialization stage, integrating research and development, production, and sales capabilities, with a pipeline of innovative drugs under research. As of the disclosure date of the prospectus, HAIXI PHARMA has 15 approved generic drug products, covering multiple therapeutic areas, including the digestive system, cardiovascular system, endocrine system, and nervous system. The company has also established a pipeline of four innovative drugs under research, covering cancer, ophthalmology, and respiratory diseases. HAIXI PHARMA previously stated in its prospectus that it plans to actively explore opportunities for collaboration with multinational companies (MNCs) in the future to expand the company's international clinical research and commercialization capabilities

    Zhitong·
    HK
    02637
    +0.53%
    Zhitong·
    HK
    02637
    +0.53%

    "New Stocks" HAIXI PHARMA half-day closing at 110.2 yuan, up 27.5% from the listing price

    HAIXI PHARMA listed on its first day, opening at 102 yuan, up 18.1% from the listing price of 86.4 yuan. The highest/lowest prices were 117.8/100 yuan, closing at 110.2 yuan, up 27.5% from the listing price of 86.4 yuan. The half-day trading volume was 1.92 million shares, involving 219 million yuan

    AASTOCKS·
    HK
    02637
    +0.53%
    AASTOCKS·
    HK
    02637
    +0.53%

    New Stock Debut | HAIXI PHARMA listed on its first day with an opening increase of 18.02%, with four core generic drugs contributing over 90% of its revenue

    HAIXI PHARMA listed on its first day, opening up 18.02%, with a share price of HKD 86.40, issuing 11.5 million shares and net fundraising of approximately HKD 940 million. The current stock price is HKD 102, with a trading volume of HKD 142 million. The company's core generic drugs contribute over 90% of its revenue, with expected revenue of HKD 425 million in 2024. Its innovative drug pipeline includes several drugs under research, with the fastest, C019199, expected to enter Phase III trials in the second half of the year

    Zhitong·
    HK
    02637
    +0.53%
    Zhitong·
    HK
    02637
    +0.53%

    HAIXI PHARMA's above-limited price public offering in Hong Kong received 3,165.1 times subscription

    HAIXI PHARMA announced its global offering results, issuing 11.5 million H shares, with 10% allocated to the Hong Kong public offering and 90% to the international offering. The offer price per share is HKD 86.40, with a net fundraising of approximately HKD 940 million from the global offering. The subscription multiple for the Hong Kong public offering is 3165.1 times, while the international offering is 6.3 times. H shares are expected to begin trading on the Stock Exchange of Hong Kong on October 20, 2025

    Zhitong·
    HK
    02637
    +0.53%
    Zhitong·
    HK
    02637
    +0.53%
    © 2025 Longbridge｜Disclaimer